Neglect of the coronary circulation: Some critical remarks on problems in the translation of cardioprotection

Cardiovascular Research

Volumn 84, Issue 1, 2009, Pages 11-14

  Heusch, Gerd ^a   Schulz, Rainer ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE;

ACUTE HEART INFARCTION; ARTIFICIAL EMBOLISM; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY MICROEMBOLIZATION; EDITORIAL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART PROTECTION; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION; EMBOLISM; HEART INFARCTION PREVENTION; PATHOPHYSIOLOGY; REPERFUSION INJURY;

CORONARY ARTERY DISEASE; CORONARY CIRCULATION; EMBOLISM; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY;

EID: 70449485631     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp210     Document Type: Editorial

References (68)

1. Braunwald E. Reduction of myocardial-infarct size. N Engl J Med 1974; 291:525-526.
2. Sutton MStJ, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction. Circulation 1997;96:3294-3299.
3. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002;39:30-36.
4. Maroko PR, Libby P, Ginks WR, Bloor CM, Shell WE, Sobel BE et al. Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest 1972;51:2710-2716.
5. Ginks WR, Sybers HD, Maroko PR, Covell JW, Sobel BE, Ross J Jr. Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest 1972;51:2717-2723.
6. Ross J Jr. Early revascularization after coronary occlusion. Circulation 1974;50:1061-1062.
7. Heusch G. Postconditioning. Old wine in a new bottle ? J Am Coll Cardiol 2004;44:1111-1112.
8. Hausenloy DJ, Yellon DM. Time to take myocardial reperfusion injury seriously. N Engl J Med 2008;359:518-520.
9. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74: 1124-1136.
10. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA et al. Inhibition of myocardial injury by ischemic postconditioning during reper-fusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
11. Heusch G. Nitroglycerin and delayed preconditioning in humans. Yet another new mechanism for an old drug? Circulation 2001;103: 2876-2878.
12. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008;118:1915-1919.
13. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 2008;103:501-513.
14. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J 2009;73:1171-1177.
15. Peart JN, Headrick JP. Clinical cardioprotection and the value of conditioning responses. Am J Physiol Heart Circ Physiol 2009;296: H1705-H1720.
16. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduc-tion of ischemic preconditioning. Cardiovasc Res 2001;52:181-198.
17. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I et al. Postcondi-tioning the human heart. Circulation 2005;112:2143-2148.
18. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G et al. Long-term benefit of postconditioning. Circulation 2008;117:1037-1044.
19. Darling CE, Solari PB, Smith CS, Furman MI, Przyklenk K. 'Postcondition-ing' the human heart: multiple balloon inflations during primary angio-plasty may confer cardioprotection. Basic Res Cardiol 2007;102:274-278.
20. Hausenloy DJ, Yellon DM. Clinical translation of cardioprotective strategies: report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection. Basic Res Cardiol 2008;103: 493-500.
21. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with aging. Cardiovasc Res 2009;83:247-261.
22. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007;59:418-458.
23. Erbel R, Heusch G. Brief review: coronary microembolization. J Am Coll Cardiol 2000;36:22-24.
24. Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G. Coronary microembolization. Basic Res Cardiol 2006;101:373-382.
25. Schulz R, Rose J, Post H, Heusch G. Involvement of endogenous adenosine in ischaemic preconditioning in swine. Pflügers Arch 1995;430:273-282.
26. Hori M, Inoue M, Kitakaze M, Koretsune Y, Iwai K, Tamai J et al. Role of adenosine in hyperemic response of coronary blood flow in microcircula-tion. Am J Physiol Heart Circ Physiol 1986;250:H509-H518.
27. Skyschally A, Schulz R, Gres P, Konietzka I, Martin C, Haude M et al. Coronary microembolization does not induce acute preconditioning against infarction in pigs-the role of adenosine. Cardiovasc Res 2004;63: 313-322.
28. Skyschally A, Gres P, Heusch P, Martin C, Haude M, Erbel R et al. Prein-farction angina: no interference of coronary microembolization with acute ischemic preconditioning. J Mol Cell Cardiol 2005;39:355-361.
29. Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R et al. Bidirectional role of tumor necrosis factor-alpha in coronary microemboliza-tion: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 2007;100:140-146.
30. Heusch P, Skyschally A, Leineweber K, Haude M, Erbel R, Heusch G. The interaction of coronary microembolization and ischemic preconditioning: a third window of cardioprotection through TNF-alpha. Arch Med Sci 2007;2:83-92.
31. Venugopal V, Ludman A, Yellon DM, Hausenloy DJ. 'Conditioning' the heart during surgery. Eur J Cardiothorac Surg 2009;35:977-987.
32. Okamoto F, Allen BS, Buckberg GD, Bugyi H, Leaf J. Studies of controlled reperfusion after ischemia. XIV. Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg 1986;92:613-620.
33. Peng CF, Murphy ML, Colwell K, Straub KD. Controlled versus hyperemic flow during reperfusion of jeopardized ischemic myocardium. Am Heart J 1989;117:515-522.
34. Pisarenko OI, Shulzhenko VS, Studneva IM, Kapelko VI. Effects of gradual reperfusion on postischemic metabolism and functional recovery of isolated guinea pig heart. Biochem Med Metab Biol 1993;50:127-134.
35. Sato H, Jordan JE, Zhao Z-Q, Sarvotham SS, Vinten-Johansen J. Gradual reperfusion reduces infarct size and endothelial injury but augments neutrophil accumulation. Ann Thorac Surg 1997;64:1099-1107.
36. Granato JE, Watson DD, Flanagan TL, Beller GA. Myocardial thallium-201 kinetics and regional flow alterations with 3 h of coronary occlusion and either rapid reperfusion through a totally patent vessel or slow reperfu-sion through a critical stenosis. J Am Coll Cardiol 1987;9:109-118.
37. Bopassa JC, Michel P, Gateau-Roesch O, Ovize M, Ferrera R. Low-pressure reperfusion alters mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 2005;288:H2750-H2755. (Pubitemid 40720654)
38. Bopassa JC, Nemlin C, Sebbag L, Rodriguez C, Ovize M, Ferrera R. Optimal time duration for low-pressure controlled reperfusion to efficiently protect ischemic rat heart. Transplant Proc 2007;39:2615-2616.
39. Musiolik J, van Caster P, Skyschally A, Boengler K, Schilawa D, Gres P et al. Gentle reperfusion reduces infarct size without activation of reper-fusion injury salvage kinases in pigs. Clin Res Cardiol 2009;98(Suppl. 1): P194.
40. Tanaka A, Kawarabayashi T, Nishibori Y, Sano T, Nishida Y, Fukuda D et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 2002;105:2148-2152. (Pubitemid 34517157)
41. Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, Boura J et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1739-1746.
42. Kammler J, Kypta A, Hofmann R, Kerschner K, Grund M, Sihorsch K et al. TIMI 3 flow after primary angioplasty is an important predictor for outcome in patients with acute myocardial infarction. Clin Res Cardiol 2009;98:165-170.
43. Mehta RH, Ou FS, Peterson ED, Shaw RE, Hillegass WB Jr, Rumsfeld JS et al. Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv 2009;2:56-64.
44. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;87: 1792-1805.
45. Herrmann J, Haude M, Lerman A, Schulz R, Volbracht L, Ge J et al. Abnormal coronary flow velocity reserve following coronary intervention is associated with cardiac marker elevation. Circulation 2001;103: 2339-2345.
46. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C et al. Pre-procedural statin medication reduces the extent of peri-procedural non-Q-wave myocardial infarction. Circulation 2002;106: 2180-2183.
47. Bahrmann P, Werner GS, Heusch G, Ferrari M, Poerner TC, Voss A et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation 2007;115:600-608.
48. Deussen A, Möser G, Schrader J. Contribution of coronary endothelial cells to cardiac adenosine production. Pflügers Arch 1986;406:608-614.
49. Faigle M, Seessle J, Zug S, El Kasmi KC, Eltzschig HK. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS ONE 2008;3:e2801.
50. Dörge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I et al. Coronary microembolization: the role of TNFa in contractile dysfunction. J Mol Cell Cardiol 2002;34:51-62.
51. Schulz R, Aker S, Belosjorow S, Heusch G. TNFa in ischemia/reperfusion injury and heart failure. Basic Res Cardiol 2004;99:8-11.
52. Iliodromitis EK, Zoga A, Vrettou A, Andreadou I, Paraskevaidis IA, Kaklamanis L et al. The effectiveness of postconditioning and preconditioning on infarct size in hypercholesterolemic and normal anesthetized rabbits. Atherosclerosis 2006;188:356-362.
53. Schulz R, Rose J, Skyschally A, Heusch G. Bradycardic agent UL-FS 49 attenuates ischemic regional dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol. J Cardiovasc Pharmacol 1995;25:216-228.
54. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine-protection beyond heart rate reduction. Eur Heart J 2008;29:2265-2275.
55. Lochner A, Genade S, Tromp E, Podzuweit T, Moolman JA. Ischemic preconditioning and the b-adrenergic signal transduction pathway. Circulation 1999;100:958-966.
56. Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A et al. Desflurane-induced postconditioning is mediated by beta-adrenergic signaling: role of beta 1-and beta 2-adrenergic receptors, protein kinase A, and calcium/calmodulin-dependent protein kinase II. Anesthesiology 2009;110:516-528.
57. Oikawa M, Yaoita H, Watanabe K, Maruyama Y. Attenuation of cardiopro-tective effect by postconditioning in coronary stenosed rat heart and its restoration by carvedilol. Circ J 2008;72:2081-2086.
58. Heusch G. Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol 2008;155:970-971.
59. Jalowy A, Schulz R, Dörge H, Behrends M, Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998;32:1787-1796.
60. Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism. Br J Pharmacol 2000;131:138-144.
61. Schulz R, Post H, Vahlhaus C, Heusch G. Ischemic preconditioning in pigs: a graded phenomenon. Its relation to adenosine and bradykinin. Circulation 1998;98:1022-1029.
62. Penna C, Mancardi D, Tullio F, Pagliaro P. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 2008;103:368-377.
63. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfu-sion injury. Cardiovasc Res 2004;61:402-413.
64. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006;40:16-23.
65. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 2007;152:855-869.
66. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardiopro-tection-more than just lipid lowering? Pharmacol Ther 2009;122:30-43.
67. Schulz R. Pleiotropic effects of statins. Acutely good, but chronically bad. J Am Coll Cardiol 2005;45:1292-1294.
68. Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E et al. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 2008;294:H2406-H2409.